Skip to main content

Table 3 Correlation between serum PIVKA-II levels and clinicopathological characteristics in HCC

From: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

Characteristics N (%) PIVKA-II (mAU/mL)
Median (Interquartile range)
P value
Age (year)
 <55 70 (41.67) 290.90 (61.32–1474.00)  
 >55 98 (58.33) 156.30 (59.87–1264.00) 0.7477
Sex
 Male 117 (69.64) 172.40 (61.50–1212.00)  
 Female 51 (30.36) 243.60 (45.23–1559.00) 0.6755
Tumor size
 <5 cm 53 (31.55) 127.00 (52.28–355.90)  
 >5 cm 115 (68.45) 440.60 (62.74–2000.00) < 0.01
Tumor number
 Single 137 (81.55) 166.30 (46.55–1151.00)  
 Multiple 31 (18.45) 515.00 (109.80–6623.00) 0.0143
Tumor stage
 I 48 (28.57) 62.41 (25.43–412.00)  
 II 57 (33.93) 174.30 (73.43–1059.00)  
 III 26 (15.48) 775.9 (159.79–2241.00)  
 IV 37 (22.02) 1854.00 (255.40–10,438.00) < 0.01
Lymph node metastasis metastasis
 Yes 42 (25.00) 722.30 (162.00–2759.00)  
 No 126 (75.00) 147.40 (46.55–1086.00) < 0.01
Distant metastasis
 Yes 36 (21.43) 1745.00 (558.30–10,342.00)  
 No 132 (78.57) 128.50 (44.04–710.90) < 0.01
Gross type
 Nodular 23 (13.69) 328.20 (62.74–1854.00)  
 Massive 93 (55.36) 185.40 (68.05–1394.00)  
 Diffuse 52 (30.95) 163.90 (44.90–1150.00) 0.6514
Differentiation degrees
 Well 42 (25.00) 60.91 (27.62–334.30)  
 Moderate 64 (38.10) 173.30 (49.39–1534.00)  
 Poor 62 (36.90) 565.10 (148.10–1886.00) < 0.01
Complications
 Yes 45 (26.79) 713.40 (184.00–3232.00)  
 No 123 (73.21) 117.70 (42.34–1056.00) < 0.01